Ryan Specialty Stock Plummets -12% With 10-Day Losing Streak
Ryan Specialty (RYAN) – a provider of specialty insurance products and solutions – hit a 10-day losing streak, with cumulative losses over this period amounting to -12%. The company’s market cap has crashed by about $574 Mil over the last 10 days and currently stands at $4.1 Bil.
Is this opportunity or trap? There are only a couple of things to fear in RYAN stock given its overall Strong operating performance and financial condition. Hence, together with its High valuation, this makes the stock look Risky (For details, see Buy or Sell RYAN).
But here is the interesting part. You are reading about this -12% move after it happened. The market has already priced in the news. To manage individual stock risk before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to manage stock-specific drawdowns better.
Returns vs S&P 500
- What Is Driving Biogen’s Recent Drop and What Comes Next
- Does Caterpillar Stock Still Have Room to Run?
- Cash Machine Trading Cheap – Centene Stock Set to Run?
- Can a $25B Investment Surge Sustain Micron’s 20% AI Memory Grab?
- The Hidden Dangers Facing Apple Stock
- How to Get Paid to Buy PYPL at a Steep Discount
The following table summarizes the return for RYAN stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | RYAN | S&P 500 |
|---|---|---|
| 1D | -3.9% | -1.7% |
| 10D (Current Streak) | -12.3% | -4.0% |
| 1M (21D) | -19.1% | -7.8% |
| 3M (63D) | -38.6% | -8.1% |
| YTD 2026 | -38.3% | -7.0% |
| 2025 | -18.9% | 16.4% |
| 2024 | 50.9% | 23.3% |
| 2023 | 3.6% | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 30 S&P constituents with 3 days or more of consecutive gains and 75 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 3 | 43 |
| 4D | 10 | 23 |
| 5D | 16 | 5 |
| 6D | 0 | 1 |
| 7D or more | 1 | 3 |
| Total >=3 D | 30 | 75 |
Key Financials for Ryan Specialty (RYAN)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $2.5 Bil | $3.1 Bil |
| EBT | $272.6 Mil | $293.2 Mil |
| Net Income | $94.7 Mil | $63.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $754.6 Mil | $751.2 Mil |
| EBT | $59.8 Mil | $44.6 Mil |
| Net Income | $31.1 Mil | $8.0 Mil |
The losing streak RYAN stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.